ReviewmAbs
Developments and opportunities in continuous biopharmaceutical manufacturing.
Review in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Industrial Bioreactor Technologies for Modern Biomanufacturing: Recent Applications in Microbial, Mammalian, and Plant-Based Systems.Molecular biotechnology · 2026Review
- A continuous viral vaccine biomanufacturing platform utilizing multiple bioreactor configurations.Journal of biological engineering · 2026Article
- Advancing Raman Calibration: Automated Data Generation, Monitoring, and Control in Multi-Parallel Perfusion Mini Bioreactors.Biotechnology journal · 2026Article
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.Frontiers in pediatrics · 2026Article
- Review
- Integration of Single Pass Tangential Flow Filtration and High Performance Countercurrent Membrane Purification for Intensification of Monoclonal Antibody Processing.Biotechnology and bioengineering · 2025Article
- Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparative Approaches for Quantification of Product Yield in the Production of Recombinant Green Fluorescent Protein (GFPuv) Expressed inbioRxiv : the preprint server for biology · 2025Article
- Purification of Human Immunoglobulin G with Bathophenanthroline-ZnAntibodies (Basel, Switzerland) · 2025Article
- Enhancing the Performance of Tangential Flow Microfiltration for Bioreactor Clarification.Membranes · 2025Article
- Cell culture media and Raman spectra preprocessing procedures impact glucose chemometrics.Journal of chemometrics · 2025Article
- Quality by design for mRNA platform purification based on continuous oligo-dT chromatography.Molecular therapy. Nucleic acids · 2024Article
- Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery-A Humanitarian Cause.International journal of molecular sciences · 2024Review
- Process intensification for lentiviral vector manufacturing using tangential flow depth filtration.Molecular therapy. Methods & clinical development · 2023Article
- Understanding the Residence Time Distribution in a Transient Inline Spiking System: Modeling, Experiments, and Simulations.Membranes · 2023Article
- Biomolecular Fishing: Design, Green Synthesis, and Performance of l-Leucine-Molecularly Imprinted Polymers.ACS omega · 2023Article
- Mixed-Mode Chromatography and Its Role in Monoclonal Antibody Purification.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Model predictive control for steady-state performance in integrated continuous bioprocesses.Bioprocess and biosystems engineering · 2022Article
- Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today's biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of consistent-quality drugs at a lower cost and a faster pace, to meet growing demand. Efficient use of equipment, manufacturing footprint, and labor also offer the potential to improve drug accessibility. Although technological efforts enabling continuous biomanufacturing have commenced, challenges remain in the integration, monitoring, and control of traditionally segmented unit operations. Here, we discuss recent developments supporting the implementation of continuous biomanufacturing, along with their benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.